Peptides Russia FDA debate sharpened in early 2026 after Health and Human Services Secretary Robert F Kennedy Jr announced that 14 of 19 peptides previously placed on the FDA’s restricted Category 2 list would return to Category 1. Compounds such as Selank and Semax have sat on Russia’s official drug register for decades and the regulatory gap between the two countries is back in focus.
Also read: SARS administrative penalties from 1 May 2026: who gets fined and how to dispute
Peptides Russia FDA: what Russia approved decades ago
Russian neuroscience research developed Selank and Semax in the 1980s and 1990s. Both are registered as pharmaceuticals on Russia’s official Vidal register. Selank is prescribed for generalised anxiety, Semax for stroke recovery and cognitive symptoms. Russian regulatory approval has no automatic effect in the United States. The FDA has never reviewed either compound for safety or efficacy in any indication.
FDA reclassification in February 2026
Kennedy’s 27 February 2026 announcement covered BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV and MOTS-C among others. The 15 April 2026 update confirmed the formal removal of 12 of those compounds from Category 2. The Pharmacy Compounding Advisory Committee will start its specific evaluation at the 23 to 24 July 2026 meeting.
What Category 1 status means in 2026
The reclassification allows licensed compounding pharmacies in the United States to prepare these peptides legally when prescribed by a physician. None of the listed peptides carry FDA approval. Patients still need a written prescription from a licensed medical provider. The peptides remain unapproved drugs subject to compounding rules under Section 503A and Section 503B of the Federal Food, Drug and Cosmetic Act.
Why the regulatory gap persists
Russia’s Ministry of Health uses a registration framework with shorter clinical evidence requirements for peptide therapeutics, particularly those developed within the Soviet-era research programme. The FDA requires randomised controlled trials and a full New Drug Application before market authorisation. Cost, market size, patent status and the absence of a US sponsor for many of these molecules all weigh on whether the FDA pathway is ever pursued. Selank and Semax have never had a US sponsor file.
Frequently asked questions
Are peptides like Selank and Semax legal in the United States?
The reclassification to Category 1 means a licensed compounding pharmacy can prepare them on a valid prescription from a US physician. Importing or buying them without a prescription remains illegal. They are not FDA-approved drugs.
What does Category 1 versus Category 2 mean?
Category 1 covers bulk substances that compounding pharmacies can use under FDA discretion while their formal review is ongoing. Category 2 covers substances under significant safety concern, which compounders cannot use. Category 1 is permissive but not equivalent to FDA approval.
Has the FDA approved any of these peptides?
No. None of the peptides on the February 2026 reclassification list carry FDA approval. The PCAC review starting 23 July 2026 will assess the data on a per-molecule basis. Approval requires a separate New Drug Application from a sponsor.
What is the position in South Africa?
The South African Health Products Regulatory Authority (SAHPRA) has not registered Selank, Semax, BPC-157 or TB-500. Patients seeking access through compounding pharmacies must work with a registered medical practitioner.
Related on Nuusflits
- SARS administrative penalties from 1 May 2026: who gets fined and how to dispute
- Hantavirus outbreak 2026: origin, spread and countries hit
- DA backs Western Cape’s NHI Constitutional Court challenge
Source: FDA, Peptide Database, SAHPRA
